Reviewing Ocular Therapeutix (OCUL) and Its Peers

Ocular Therapeutix (NASDAQ: OCUL) is one of 90 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare Ocular Therapeutix to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.

Risk and Volatility

Ocular Therapeutix has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Ocular Therapeutix’s peers have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ocular Therapeutix and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix 0 2 5 0 2.71
Ocular Therapeutix Competitors 213 1307 2853 101 2.64

Ocular Therapeutix presently has a consensus price target of $22.29, indicating a potential upside of 315.00%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.17%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than its peers.

Earnings and Valuation

This table compares Ocular Therapeutix and its peers revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Ocular Therapeutix $1.89 million -$44.70 million -2.36
Ocular Therapeutix Competitors $1.09 billion $127.35 million 196.77

Ocular Therapeutix’s peers have higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Ocular Therapeutix and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocular Therapeutix -3,241.19% -126.31% -81.51%
Ocular Therapeutix Competitors -129.01% -39.34% -10.36%

Insider and Institutional Ownership

52.4% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 68.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 11.3% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Ocular Therapeutix peers beat Ocular Therapeutix on 7 of the 12 factors compared.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with's FREE daily email newsletter.

Leave a Reply